Tong Yin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Tong Yin has a total of 172 co-authors. Here are the top co-authors by number of shared publications:
Chao Lv
Institute of Geriatrics, National Clinical Research Center for Geriatric Diseases, The Second Medical Center of Chinese PLA General Hospital, 100853 Beijing, China
11 shared publicationsJie Yang
Department of Cardiology, Institute of Geriatric Cardiology, General Hospital of Chinese People's Liberation Army, Beijing 100853, China
11 shared publicationsYuxiao Zhang
Institute of Geriatrics, National Clinical Research Center for Geriatric Diseases, 2nd Medical Center, Medical School of Chinese People's Liberation Army and Chinese People's Liberation Army General Hospital, Beijing, China
9 shared publicationsQiang Xu
Department of Cardiology, Institute of Geriatric Cardiology, General Hospital of Chinese People's Liberation Army, Beijing 100853, China
8 shared publicationsXuyun Wang
Department of Cardiology, First Medical Center & National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing, China
8 shared publicationsYangxun Wu
Institute of Geriatrics, Beijing Key Laboratory of Geriatric Multimorbidity Research, National Clinical Research Center for Geriatric Diseases, the Second Medical Center, Chinese PLA General Hospital
8 shared publications
Latest Publications
- Open Access
- 22 October 2026
- Published by IMR Press in Reviews in Cardiovascular Medicine
- Vol. 27 (10)
Association Between Platelet Count/Lactate Dehydrogenase Ratio and In-Hospital Mortality in the Patients With Sepsis-Induced Myocardial Injury
Background: Sepsis-induced myocardial injury (SIMI) is a severe complication with high mortality, yet effective prognostic prediction tools remain limited. Although platelet-derived indices have been explored in SIMI, these metrics primarily reflect systemic inflammation rather than the extent of myocardial injury or metabolic status. Methods: We retrospectively analyzed 3071 critically ill individuals with SIMI admitted to the intensive care unit (ICU) of the Chinese People’s Liberation Army (PLA) General Hospital between January 2020 and October 2025. The association between the platelet count (PLT)/lactate dehydrogenase (LDH) ratio and in-hospital mortality was assessed using multivariable Cox regression, restricted cubic splines, and receiver operating characteristic (ROC) curve analysis. Subgroup analyses evaluated consistency across clinically relevant strata. Results: The PLT/LDH ratio was independently associated with lower in-hospital mortality (hazard ratio [HR] = 0.44, 95% confidence interval [CI]: 0.34–0.57, p < 0.001). Compared with the lowest tertile, the highest tertile of PLT/LDH ratio was associated with a 67% reduction in risk (HR = 0.33, 95% CI: 0.25–0.43, p < 0.001). The PLT/LDH ratio demonstrated modest, statistically significant incremental discriminative performance over PLT or LDH alone (both p < 0.05). A nonlinear relationship was observed, with an inflection point at approximately 0.306 (p for nonlinearity < 0.0001). Subgroup analyses revealed a consistent association across all subgroups, with significant interactions for sex, hypertension, chronic kidney disease, and liver disease (all p for interaction < 0.05). Conclusions: The PLT/LDH ratio is independently associated with in-hospital mortality in patients with SIMI. It may serve as a simple and practical tool for prognostic prediction in patients with SIMI upon ICU admission.
- 22 October 2026
- Published by IMR Press in Reviews in Cardiovascular Medicine
- Vol. 27 (10)
Open AccessAssociation Between Platelet Count/Lactate Dehydrogenase Ratio and In-Hospital Mortality in the Patients With Sepsis-Induced Myocardial Injury
Background: Sepsis-induced myocardial injury (SIMI) is a severe complication with high mortality, yet effective prognostic prediction tools remain limited. Although platelet-derived indices have been explored in SIMI, these metrics primarily reflect systemic inflammation rather than the extent of myocardial injury or metabolic status. Methods: We retrospectively analyzed 3071 critically ill individuals with SIMI admitted to the intensive care unit (ICU) of the Chinese People’s Liberation Army (PLA) General Hospital between January 2020 and October 2025. The association between the platelet count (PLT)/lactate dehydrogenase (LDH) ratio and in-hospital mortality was assessed using multivariable Cox regression, restricted cubic splines, and receiver operating characteristic (ROC) curve analysis. Subgroup analyses evaluated consistency across clinically relevant strata. Results: The PLT/LDH ratio was independently associated with lower in-hospital mortality (hazard ratio [HR] = 0.44, 95% confidence interval [CI]: 0.34–0.57, p < 0.001). Compared with the lowest tertile, the highest tertile of PLT/LDH ratio was associated with a 67% reduction in risk (HR = 0.33, 95% CI: 0.25–0.43, p < 0.001). The PLT/LDH ratio demonstrated modest, statistically significant incremental discriminative performance over PLT or LDH alone (both p < 0.05). A nonlinear relationship was observed, with an inflection point at approximately 0.306 (p for nonlinearity < 0.0001). Subgroup analyses revealed a consistent association across all subgroups, with significant interactions for sex, hypertension, chronic kidney disease, and liver disease (all p for interaction < 0.05). Conclusions: The PLT/LDH ratio is independently associated with in-hospital mortality in patients with SIMI. It may serve as a simple and practical tool for prognostic prediction in patients with SIMI upon ICU admission.
- Open Access
- 10 September 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1860173
Mortality prediction in the elderly patients with coronary artery disease and atrial fibrillation: a retrospective machine learning approach
Background: Elderly patients with coexisting coronary artery disease (CAD) and atrial fibrillation (AF) are at significantly increased risk of mortality. Accurate risk stratification is crucial for improving clinical management, yet a dedicated predictive tool for this specific population is lacking. The widely used CHA 2 DS 2 -VASc score demonstrates limited performance in predicting all-cause mortality in this complex comorbid group. Methods: A cohort of elderly inpatients (≥65 years) diagnosed with CAD and AF were retrospectively enrolled from the Department of Cardiology at the Chinese PLA General Hospital between January 2010 and December 2017. Baseline clinical data during hospitalization were collected, and all patients were followed up for all-cause mortality. Patients were randomly divided into a training set (70%) and a validation set (30%). Variable selection was performed using LASSO-Cox regression. Predictive models were established through a Cox proportional hazards model (via LASSO-Cox) to predict all-cause mortality risk. To assess model robustness and address potential overfitting, we performed 10-fold cross-validation and bootstrap resampling (500 replicates) with optimism-corrected C-statistics. Model performance was evaluated using the area under the receiver operating characteristic curve (AUC), calibration curves, and decision curve analysis (DCA), and compared against the CHA 2 DS 2 -VASc score. Results: A total of 1678 elderly patients with CAD and AF were randomly divided into a training set ( n = 1174) and a validation set ( n = 504). Through LASSO-Cox regression, 17 variables were identified as predictors associated with all-cause mortality. Two distinct models were developed: LASSO-Cox Model A included factors such as age, left ventricular ejection fraction, blood glucose, plasma fibrinogen, D-dimer, prothrombin time, NT-proBNP, hemoglobin, and hematocrit; LASSO-Cox Model B incorporated all variables from Model A plus acute myocardial infarction, history of myocardial infarction, renal insufficiency, heart failure, diabetes, stroke, chronic obstructive pulmonary disease, and malignant tumor. The analysis of Cox proportional hazards regression models showed that in the training sets, the Area Under Curves (AUC) of model A, model B and CHA 2 DS 2 -VASc scores for predicting 1-year all-cause death were 0.83, 0.85 and 0.66, respectively; the AUC for 5-year all-cause death were 0.74, 0.76 and 0.62, respectively. In the validation sets, the AUC of model A, model B and the CHA 2 DS 2 -VASc score for predicting 1-year all-cause mortality were 0.79, 0.78 and 0.57, respectively; the AUC for 5-year all-cause death were 0.74, 0.75 and 0.57, respectively. The 10-fold cross-validation yielded a mean AUC of 0.83 (SD: 0.04) for 1-year mortality, and bootstrap resampling produced an optimism-corrected C-statistic of 0.679 (95% CI: 0.651–0.708), confirming that the model maintains clinically meaningful discriminative ability after accounting for optimism. Model B demonstrated better calibration and provided greater net clinical benefit in DCA. Conclusion: The LASSO-Cox machine learning model demonstrates superior predictive performance for all cause mortality relative to the traditional CHA 2 DS 2 -VASc score in elderly patients with CAD and AF.
- 10 September 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1860173
Open AccessMortality prediction in the elderly patients with coronary artery disease and atrial fibrillation: a retrospective machine learning approach
Background: Elderly patients with coexisting coronary artery disease (CAD) and atrial fibrillation (AF) are at significantly increased risk of mortality. Accurate risk stratification is crucial for improving clinical management, yet a dedicated predictive tool for this specific population is lacking. The widely used CHA 2 DS 2 -VASc score demonstrates limited performance in predicting all-cause mortality in this complex comorbid group. Methods: A cohort of elderly inpatients (≥65 years) diagnosed with CAD and AF were retrospectively enrolled from the Department of Cardiology at the Chinese PLA General Hospital between January 2010 and December 2017. Baseline clinical data during hospitalization were collected, and all patients were followed up for all-cause mortality. Patients were randomly divided into a training set (70%) and a validation set (30%). Variable selection was performed using LASSO-Cox regression. Predictive models were established through a Cox proportional hazards model (via LASSO-Cox) to predict all-cause mortality risk. To assess model robustness and address potential overfitting, we performed 10-fold cross-validation and bootstrap resampling (500 replicates) with optimism-corrected C-statistics. Model performance was evaluated using the area under the receiver operating characteristic curve (AUC), calibration curves, and decision curve analysis (DCA), and compared against the CHA 2 DS 2 -VASc score. Results: A total of 1678 elderly patients with CAD and AF were randomly divided into a training set ( n = 1174) and a validation set ( n = 504). Through LASSO-Cox regression, 17 variables were identified as predictors associated with all-cause mortality. Two distinct models were developed: LASSO-Cox Model A included factors such as age, left ventricular ejection fraction, blood glucose, plasma fibrinogen, D-dimer, prothrombin time, NT-proBNP, hemoglobin, and hematocrit; LASSO-Cox Model B incorporated all variables from Model A plus acute myocardial infarction, history of myocardial infarction, renal insufficiency, heart failure, diabetes, stroke, chronic obstructive pulmonary disease, and malignant tumor. The analysis of Cox proportional hazards regression models showed that in the training sets, the Area Under Curves (AUC) of model A, model B and CHA 2 DS 2 -VASc scores for predicting 1-year all-cause death were 0.83, 0.85 and 0.66, respectively; the AUC for 5-year all-cause death were 0.74, 0.76 and 0.62, respectively. In the validation sets, the AUC of model A, model B and the CHA 2 DS 2 -VASc score for predicting 1-year all-cause mortality were 0.79, 0.78 and 0.57, respectively; the AUC for 5-year all-cause death were 0.74, 0.75 and 0.57, respectively. The 10-fold cross-validation yielded a mean AUC of 0.83 (SD: 0.04) for 1-year mortality, and bootstrap resampling produced an optimism-corrected C-statistic of 0.679 (95% CI: 0.651–0.708), confirming that the model maintains clinically meaningful discriminative ability after accounting for optimism. Model B demonstrated better calibration and provided greater net clinical benefit in DCA. Conclusion: The LASSO-Cox machine learning model demonstrates superior predictive performance for all cause mortality relative to the traditional CHA 2 DS 2 -VASc score in elderly patients with CAD and AF.
- Open Access
- 21 July 2026
- Published by IMR Press in British Journal of Hospital Medicine
- Vol. 87 (7)
Platelet-To-Lactate Ratio Predicts In-Hospital Mortality in Patients With Sepsis-Induced Coagulopathy: A Retrospective Cohort Study
Aims/Background:Sepsis-induced coagulopathy (SIC) is a life-threatening complication with high mortality. The platelet count reflects coagulation status, and the lactate level indicates tissue hypoperfusion, although the prognostic value of these individual parameters is limited. The platelet-to-lactate ratio (PLAC) integrates these parameters, but its prognostic role in SIC is unclear. Here, we investigated the association between the PLAC and in-hospital mortality in patients with SIC.Methods:This retrospective cohort study included patients with SIC who were diagnosed after admission to the intensive care unit (ICU) of Chinese PLA General Hospital between December 2017 and October 2025. Multivariate Cox regression was used to assess the association between the PLAC and mortality. Restricted cubic spline (RCS) analysis was used to explore nonlinear relationships and threshold effects. The predictive performance of the PLAC was compared with that of the Sequential Organ Failure Assessment (SOFA) score, the SIC score, and the Charlson comorbidity index score using receiver operating characteristic (ROC) curves and the DeLong test.Results:Among 1722 patients with SIC, the in-hospital mortality was 26.2% (n = 452). Nonsurvivors had significantly lower PLAC values than did survivors (13.44 vs. 32.75, p < 0.001). Compared with the highest PLAC tertile, the middle and lowest tertiles had significantly higher mortality risk [adjusted hazard ratios (HRs): 1.701 and 3.501, respectively; both p < 0.05]. RCS analysis revealed a threshold effect at PLAC = 28. The area under the curve (AUC) for the PLAC was 0.711 (95% CI: 0.683–0.738), which was comparable to that of the SOFA score (p = 0.135) and superior to that of the SIC score and Charlson comorbidity index score (both p < 0.001). Subgroup analyses revealed a consistent prognostic value across most subgroups, with a significant interaction for coronary artery disease (p < 0.0001 for interaction) and Charlson score (p = 0.042).Conclusion:The PLAC is independently associated with in-hospital mortality in patients with SIC, with a clinically actionable threshold of 28. The PLAC is a simple biomarker that integrates coagulation and perfusion status and is a practical tool for risk stratification. However, multicenter prospective studies are needed to validate these findings.
- 21 July 2026
- Published by IMR Press in British Journal of Hospital Medicine
- Vol. 87 (7)
Open AccessPlatelet-To-Lactate Ratio Predicts In-Hospital Mortality in Patients With Sepsis-Induced Coagulopathy: A Retrospective Cohort Study
Aims/Background:Sepsis-induced coagulopathy (SIC) is a life-threatening complication with high mortality. The platelet count reflects coagulation status, and the lactate level indicates tissue hypoperfusion, although the prognostic value of these individual parameters is limited. The platelet-to-lactate ratio (PLAC) integrates these parameters, but its prognostic role in SIC is unclear. Here, we investigated the association between the PLAC and in-hospital mortality in patients with SIC.Methods:This retrospective cohort study included patients with SIC who were diagnosed after admission to the intensive care unit (ICU) of Chinese PLA General Hospital between December 2017 and October 2025. Multivariate Cox regression was used to assess the association between the PLAC and mortality. Restricted cubic spline (RCS) analysis was used to explore nonlinear relationships and threshold effects. The predictive performance of the PLAC was compared with that of the Sequential Organ Failure Assessment (SOFA) score, the SIC score, and the Charlson comorbidity index score using receiver operating characteristic (ROC) curves and the DeLong test.Results:Among 1722 patients with SIC, the in-hospital mortality was 26.2% (n = 452). Nonsurvivors had significantly lower PLAC values than did survivors (13.44 vs. 32.75, p < 0.001). Compared with the highest PLAC tertile, the middle and lowest tertiles had significantly higher mortality risk [adjusted hazard ratios (HRs): 1.701 and 3.501, respectively; both p < 0.05]. RCS analysis revealed a threshold effect at PLAC = 28. The area under the curve (AUC) for the PLAC was 0.711 (95% CI: 0.683–0.738), which was comparable to that of the SOFA score (p = 0.135) and superior to that of the SIC score and Charlson comorbidity index score (both p < 0.001). Subgroup analyses revealed a consistent prognostic value across most subgroups, with a significant interaction for coronary artery disease (p < 0.0001 for interaction) and Charlson score (p = 0.042).Conclusion:The PLAC is independently associated with in-hospital mortality in patients with SIC, with a clinically actionable threshold of 28. The PLAC is a simple biomarker that integrates coagulation and perfusion status and is a practical tool for risk stratification. However, multicenter prospective studies are needed to validate these findings.
- Open Access
- 10 June 2026
- Published by Springer Nature in European Journal of Medical Research
- Vol. 31 (1)
Plasma circRNA expression profile in patients with early-onset acute myocardial infarction
- 10 June 2026
- Published by Springer Nature in European Journal of Medical Research
- Vol. 31 (1)
Open AccessPlasma circRNA expression profile in patients with early-onset acute myocardial infarction
- Open Access
- 9 June 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 1839835
Effect of combined aspirin and statin therapy on mortality reduction in sepsis-induced myocardial injury
Introduction: Sepsis-induced myocardial injury (SIMI) is a severe complication with high mortality and limited effective treatments. Although combined aspirin and statin therapy is cardioprotective in coronary artery disease, its impact on SIMI outcomes remains unclear. Methods: Using the MIMIC-IV database, we evaluated the association of combined aspirin and statin therapy with 28-day, 90-day, and 1-year mortality in SIMI patients using multivariable Cox regression and Kaplan-Meier analysis. Robustness was assessed via floating absolute risk analysis. External validation was performed in an independent ICU cohort. Results: Among 1,884 SIMI patients, 119 received combination therapy. Compared to those without aspirin or statin, combination therapy was associated with significantly lower mortality at 28 days (11.8% vs. 41.9%; HR = 0.22), 90 days (15.1% vs. 44.8%; HR = 0.23), and 1 year (29.4% vs. 50.9%; HR = 0.38) (all P < 0.001). The combination consistently showed the greatest risk reduction. Subgroup analysis confirmed consistent benefits. External validation (n = 4,002) confirmed a lower 28-day mortality risk with combination therapy (HR = 0.48; P < 0.001). Conclusion: Combined aspirin and statin therapy is associated with reduced mortality and improved outcomes in SIMI patients.
- 9 June 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 1839835
Open AccessEffect of combined aspirin and statin therapy on mortality reduction in sepsis-induced myocardial injury
Introduction: Sepsis-induced myocardial injury (SIMI) is a severe complication with high mortality and limited effective treatments. Although combined aspirin and statin therapy is cardioprotective in coronary artery disease, its impact on SIMI outcomes remains unclear. Methods: Using the MIMIC-IV database, we evaluated the association of combined aspirin and statin therapy with 28-day, 90-day, and 1-year mortality in SIMI patients using multivariable Cox regression and Kaplan-Meier analysis. Robustness was assessed via floating absolute risk analysis. External validation was performed in an independent ICU cohort. Results: Among 1,884 SIMI patients, 119 received combination therapy. Compared to those without aspirin or statin, combination therapy was associated with significantly lower mortality at 28 days (11.8% vs. 41.9%; HR = 0.22), 90 days (15.1% vs. 44.8%; HR = 0.23), and 1 year (29.4% vs. 50.9%; HR = 0.38) (all P < 0.001). The combination consistently showed the greatest risk reduction. Subgroup analysis confirmed consistent benefits. External validation (n = 4,002) confirmed a lower 28-day mortality risk with combination therapy (HR = 0.48; P < 0.001). Conclusion: Combined aspirin and statin therapy is associated with reduced mortality and improved outcomes in SIMI patients.
- Open Access
- 8 May 2025
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 16, 1554032
Association between hemoglobin glycation index and the risk of cardiovascular disease in early-stage cardiovascular-kidney-metabolic syndrome: evidence from the China health and retirement longitudinal study
Background: Cardiovascular-kidney-metabolic (CKM) syndrome reflects the interplay among metabolic risk factors, chronic kidney disease, and cardiovascular disease (CVD). While the hemoglobin glycation index (HGI) has demonstrated prognostic value for cardiovascular events, its clinical utility remains unexplored in early-stage CKM syndrome.Methods: Participants with early-stage CKM syndrome (stage 0-3) were recruited from the China Health and Retirement Longitudinal Study (CHARLS) database. Using k-means clustering analysis, the participants were classified according to the values of HGI measured at baseline and 3 years later, respectively. The primary outcome was self-reported CVD during the follow-up of at least 3 years. Extreme gradient boosting (XGBoost) algorithm was applied, with the Shapley additive explanation (SHAP) method used to determine feature importance. Multivariable logistics proportional regression analysis the association between HGI and CVD, and restricted cubic spline (RCS) regression assessed potential nonlinear relationships.Results: A total of 4676 eligible participants were included in the final analysis, with 944 (20.19%) progressed to CVD within 10 years. Among the baseline clinical features, HGI ranked the second for the impact on the occurrence of CVD. According to the changes of HGI values, the participants were clustered into 4 classes. Compared to the class 1 with lower level of HGI, higher risk of CVD was observed in class 3 (adjusted OR: 1.34, 95% CI: 1.06-1.69, P = 0.013) and class 4 (adjusted OR: 1.65, 95% CI: 1.01-2.45, P = 0.025) with higher and rapidly increasing level of HGI. RCS analysis showed cumulative HGI and the risk of CVD were linearly related (P for nonlinearity = 0.967). Subgroup analyses confirmed the stability of the association. Additionally, the SHAP plot revealed that HGI were the more important features than traditional risk factors such as FBG for predicting CVD.Conclusion: HGI is associated with an elevated risk of CVD in participants with early-stage CKM syndrome. HGI can serve as an independent biomarker for guiding clinical decision-making and managing patient outcomes.
- 8 May 2025
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 16, 1554032
Open AccessAssociation between hemoglobin glycation index and the risk of cardiovascular disease in early-stage cardiovascular-kidney-metabolic syndrome: evidence from the China health and retirement longitudinal study
Background: Cardiovascular-kidney-metabolic (CKM) syndrome reflects the interplay among metabolic risk factors, chronic kidney disease, and cardiovascular disease (CVD). While the hemoglobin glycation index (HGI) has demonstrated prognostic value for cardiovascular events, its clinical utility remains unexplored in early-stage CKM syndrome.Methods: Participants with early-stage CKM syndrome (stage 0-3) were recruited from the China Health and Retirement Longitudinal Study (CHARLS) database. Using k-means clustering analysis, the participants were classified according to the values of HGI measured at baseline and 3 years later, respectively. The primary outcome was self-reported CVD during the follow-up of at least 3 years. Extreme gradient boosting (XGBoost) algorithm was applied, with the Shapley additive explanation (SHAP) method used to determine feature importance. Multivariable logistics proportional regression analysis the association between HGI and CVD, and restricted cubic spline (RCS) regression assessed potential nonlinear relationships.Results: A total of 4676 eligible participants were included in the final analysis, with 944 (20.19%) progressed to CVD within 10 years. Among the baseline clinical features, HGI ranked the second for the impact on the occurrence of CVD. According to the changes of HGI values, the participants were clustered into 4 classes. Compared to the class 1 with lower level of HGI, higher risk of CVD was observed in class 3 (adjusted OR: 1.34, 95% CI: 1.06-1.69, P = 0.013) and class 4 (adjusted OR: 1.65, 95% CI: 1.01-2.45, P = 0.025) with higher and rapidly increasing level of HGI. RCS analysis showed cumulative HGI and the risk of CVD were linearly related (P for nonlinearity = 0.967). Subgroup analyses confirmed the stability of the association. Additionally, the SHAP plot revealed that HGI were the more important features than traditional risk factors such as FBG for predicting CVD.Conclusion: HGI is associated with an elevated risk of CVD in participants with early-stage CKM syndrome. HGI can serve as an independent biomarker for guiding clinical decision-making and managing patient outcomes.
- Open Access
- 26 October 2024
- Published by Springer Nature in BMC Geriatrics
- Vol. 24 (1) , 1-10
Drug-gene interactions in older patients with coronary artery disease
Older patients with coronary artery disease (CAD) are particularly vulnerable to the efficacy and adverse drug reactions, and may therefore particularly benefit from personalized medication. Drug–gene interactions (DGIs) occur when an individual’s genotype affects the pharmacokinetics and/or pharmacodynamics of a victim drug. This study aimed to investigate the impact of cardiovascular-related DGIs on the clinical efficacy and safety outcomes in older patients with CAD. Hospitalized older patients (≥ 65 years old) with CAD were consecutively recruited from August 2018 to May 2022. Eligible patients were genotyped for the actionable pharmacogenetic variants of CYP2C9, CYP2C19, CYP2D6, CYP3A5, and SLCO1B1, which had clinical annotations or implementation guidelines for cardiovascular drugs. Allele frequencies and DGIs were determined in the cohort for the 5 actionable PGx genes and the prescribed cardiovascular drugs. All patients were followed up for at least 1 year. The influence of DGIs on the cardiovascular drug-related efficacy outcomes (all-cause mortality and/or major cardiovascular events, MACEs) and drug response phenotypes of “drug-stop” and “dose-decrease” were evaluated. A total of 1,017 eligible older patients with CAD were included, among whom 63.2% were male, with an average age of 80.8 years old, and 87.6% were administrated with polypharmacy (≥ 5 medications). After genotyping, we found that 96.0% of the older patients with CAD patients had at least one allele of the 5 pharmacogenes associated with a therapeutic change, indicating a need for a therapeutic change in a mean of 1.32 drugs of the 19 cardiovascular-related drugs. We also identified that 79.5% of the patients had at least one DGI (range 0–6). The median follow-up interval was 39 months. Independent of age, negative association could be found between the number of DGIs and all-cause mortality (adjusted HR: 0.84, 95% CI: 0.73–0.96, P = 0.008), and MACEs (adjusted HR: 0.84, 95% CI: 0.72–0.98, P = 0.023), but positive association could be found between the number of DGIs and drug response phenotypes (adjusted OR: 1.24, 95% CI: 1.05–1.45, P = 0.011) in the elderly patients with CAD. The association between cardiovascular DGIs and the clinical outcomes emphasized the necessity for the integration of genetic and clinical data to enhance the optimization of cardiovascular polypharmacy in older patients with CAD. The causal relationship between DGIs and the clinical outcomes should be established in the large scale prospectively designed cohort study.
- 26 October 2024
- Published by Springer Nature in BMC Geriatrics
- Vol. 24 (1) , 1-10
Open AccessDrug-gene interactions in older patients with coronary artery disease
Older patients with coronary artery disease (CAD) are particularly vulnerable to the efficacy and adverse drug reactions, and may therefore particularly benefit from personalized medication. Drug–gene interactions (DGIs) occur when an individual’s genotype affects the pharmacokinetics and/or pharmacodynamics of a victim drug. This study aimed to investigate the impact of cardiovascular-related DGIs on the clinical efficacy and safety outcomes in older patients with CAD. Hospitalized older patients (≥ 65 years old) with CAD were consecutively recruited from August 2018 to May 2022. Eligible patients were genotyped for the actionable pharmacogenetic variants of CYP2C9, CYP2C19, CYP2D6, CYP3A5, and SLCO1B1, which had clinical annotations or implementation guidelines for cardiovascular drugs. Allele frequencies and DGIs were determined in the cohort for the 5 actionable PGx genes and the prescribed cardiovascular drugs. All patients were followed up for at least 1 year. The influence of DGIs on the cardiovascular drug-related efficacy outcomes (all-cause mortality and/or major cardiovascular events, MACEs) and drug response phenotypes of “drug-stop” and “dose-decrease” were evaluated. A total of 1,017 eligible older patients with CAD were included, among whom 63.2% were male, with an average age of 80.8 years old, and 87.6% were administrated with polypharmacy (≥ 5 medications). After genotyping, we found that 96.0% of the older patients with CAD patients had at least one allele of the 5 pharmacogenes associated with a therapeutic change, indicating a need for a therapeutic change in a mean of 1.32 drugs of the 19 cardiovascular-related drugs. We also identified that 79.5% of the patients had at least one DGI (range 0–6). The median follow-up interval was 39 months. Independent of age, negative association could be found between the number of DGIs and all-cause mortality (adjusted HR: 0.84, 95% CI: 0.73–0.96, P = 0.008), and MACEs (adjusted HR: 0.84, 95% CI: 0.72–0.98, P = 0.023), but positive association could be found between the number of DGIs and drug response phenotypes (adjusted OR: 1.24, 95% CI: 1.05–1.45, P = 0.011) in the elderly patients with CAD. The association between cardiovascular DGIs and the clinical outcomes emphasized the necessity for the integration of genetic and clinical data to enhance the optimization of cardiovascular polypharmacy in older patients with CAD. The causal relationship between DGIs and the clinical outcomes should be established in the large scale prospectively designed cohort study.
- Open Access
- 17 August 2024
- Published by MDPI AG in Pharmaceutics
- Vol. 16 (8) , 1079
A Pharmacogenetic Panel-Based Prediction of the Clinical Outcomes in Elderly Patients with Coronary Artery Disease
Clinical annotations for the actionable pharmacogenetic variants affecting the efficacy of cardiovascular drugs have been collected, yet their impacts on elderly patients with coronary artery disease (CAD) undergoing polypharmacy remain uncertain. We consecutively enrolled 892 elderly patients (mean age 80.7 ± 5.2) with CAD and polypharmacy. All the included patients underwent genotyping for 13 variants in 10 pharmacogenes (CYP2C19, CYP2C9, CYP4F2, CYP2D6, VKORC1, SLCO1B1, APOE, ACE, ADRB1, and MTHFR), which have the clinical annotations for 12 drugs that are commonly prescribed for patients with CAD. We found that 80.3% of the elderly CAD patients had at least one drug–gene pair associated with a therapeutical drug change. After adjusting for covariates, the number of drug–gene pairs was independently associated with a decreased risk of both major cardiovascular events (MACEs) (adjusted hazard ratio [HR]: 0.803, 95% confidence interval [CI]: 0.683–0.945, p = 0.008) and all-cause mortality (adjusted HR: 0.848, 95% CI: 0.722–0.996, p = 0.045), but also with an increased risk of adverse drug reactions (ADRs) (adjusted HR: 1.170, 95% CI: 1.030–1.329, p = 0.016). The Kaplan–Meier survival curves showed that compared to patients without a drug–gene pair, a significantly lower risk of MACEs could be observed in patients with a drug–gene pair during a 4-year follow-up (HR: 0.556, 95% CI: 0.325–0.951, p = 0.013). In conclusion, the carrier status of the actionable drug–gene pair is predictive for the clinical outcomes in elderly patients with CAD and polypharmacy. Implementing early or preemptive pharmacogenetic panel-guided polypharmacy holds the potential to enhance clinical outcomes for these patients.
- 17 August 2024
- Published by MDPI AG in Pharmaceutics
- Vol. 16 (8) , 1079
Open AccessA Pharmacogenetic Panel-Based Prediction of the Clinical Outcomes in Elderly Patients with Coronary Artery Disease
Clinical annotations for the actionable pharmacogenetic variants affecting the efficacy of cardiovascular drugs have been collected, yet their impacts on elderly patients with coronary artery disease (CAD) undergoing polypharmacy remain uncertain. We consecutively enrolled 892 elderly patients (mean age 80.7 ± 5.2) with CAD and polypharmacy. All the included patients underwent genotyping for 13 variants in 10 pharmacogenes (CYP2C19, CYP2C9, CYP4F2, CYP2D6, VKORC1, SLCO1B1, APOE, ACE, ADRB1, and MTHFR), which have the clinical annotations for 12 drugs that are commonly prescribed for patients with CAD. We found that 80.3% of the elderly CAD patients had at least one drug–gene pair associated with a therapeutical drug change. After adjusting for covariates, the number of drug–gene pairs was independently associated with a decreased risk of both major cardiovascular events (MACEs) (adjusted hazard ratio [HR]: 0.803, 95% confidence interval [CI]: 0.683–0.945, p = 0.008) and all-cause mortality (adjusted HR: 0.848, 95% CI: 0.722–0.996, p = 0.045), but also with an increased risk of adverse drug reactions (ADRs) (adjusted HR: 1.170, 95% CI: 1.030–1.329, p = 0.016). The Kaplan–Meier survival curves showed that compared to patients without a drug–gene pair, a significantly lower risk of MACEs could be observed in patients with a drug–gene pair during a 4-year follow-up (HR: 0.556, 95% CI: 0.325–0.951, p = 0.013). In conclusion, the carrier status of the actionable drug–gene pair is predictive for the clinical outcomes in elderly patients with CAD and polypharmacy. Implementing early or preemptive pharmacogenetic panel-guided polypharmacy holds the potential to enhance clinical outcomes for these patients.
- Open Access
- 21 June 2024
- Published by Springer Nature in Thrombosis Journal
- Vol. 22 (1) , 1-8
Platelet-derived circFAM13B associated with anti-platelet responsiveness of ticagrelor in patients with acute coronary syndrome
Background: Platelet is enriched with Circular RNAs (circRNAs), with circFAM13B rank among the 10 most abundant circRNAs in platelets. The aim of the present study was to evaluate the predictive value of platelet-derived circFAM13B for the antiplatelet responsiveness and efficacy of ticagrelor in patients with acute coronary syndrome (ACS). Methods: Consecutive ACS patients treated with ticagrelor were enrolled, and the antiplatelet responsiveness of 3 days of ticagrelor maintenance treatment was assessed by measuring the adenosine diphosphate (ADP)-induced platelet inhibition rate (ADP%) using thromboelastography. The expression of circFAM13B in the patients’ platelets was analyzed by quantitative real-time polymerase chain reaction. The correlation between circFAM13B expression and ticagrelor antiplatelet responsiveness, as well as the independent contribution of circFAM13B to the composite of adverse ischemic events during a follow-up period of at least 12 months was evaluated. Results: A total of 129 eligible ACS patients treated with ticagrelor were enrolled in the study. A negative correlation was found between the expression of circFAM13B and the ADP% value (r = -0.41, P < 0.001). Patients with ADP% ≥ 76% had a significantly lower level of circFAM13B compared to those with ADP% < 76% (adjusted P = 0.009). Receiver operating characteristic curve analysis demonstrated that combining circFAM13B expression > 1.05 with clinical risk factors could effectively predict the risk of adverse ischemic events (AUC = 0.81, 95% CI: 0.69 to 0.92, P < 0.001). Kaplan-Meier survival analysis showed that patients with circFAM13B > 1.05 had a significantly higher risk of adverse ischemic events compared to those with circFAM13B ≤ 1.05 (P = 0.003). Multivariate logistic hazard analysis identified circFAM13B > 1.05 as an independent risk factor for adverse ischemic events in in ticagrelor-treated ACS patients (adjusted OR: 5.60, 95% CI: 1.69–18.50; P = 0.005). Conclusions: Platelet-derived circFAM13B could be utilized for predicting the antiplatelet responsiveness and efficacy of ticagrelor in patients with ACS.
- 21 June 2024
- Published by Springer Nature in Thrombosis Journal
- Vol. 22 (1) , 1-8
Open AccessPlatelet-derived circFAM13B associated with anti-platelet responsiveness of ticagrelor in patients with acute coronary syndrome
Background: Platelet is enriched with Circular RNAs (circRNAs), with circFAM13B rank among the 10 most abundant circRNAs in platelets. The aim of the present study was to evaluate the predictive value of platelet-derived circFAM13B for the antiplatelet responsiveness and efficacy of ticagrelor in patients with acute coronary syndrome (ACS). Methods: Consecutive ACS patients treated with ticagrelor were enrolled, and the antiplatelet responsiveness of 3 days of ticagrelor maintenance treatment was assessed by measuring the adenosine diphosphate (ADP)-induced platelet inhibition rate (ADP%) using thromboelastography. The expression of circFAM13B in the patients’ platelets was analyzed by quantitative real-time polymerase chain reaction. The correlation between circFAM13B expression and ticagrelor antiplatelet responsiveness, as well as the independent contribution of circFAM13B to the composite of adverse ischemic events during a follow-up period of at least 12 months was evaluated. Results: A total of 129 eligible ACS patients treated with ticagrelor were enrolled in the study. A negative correlation was found between the expression of circFAM13B and the ADP% value (r = -0.41, P < 0.001). Patients with ADP% ≥ 76% had a significantly lower level of circFAM13B compared to those with ADP% < 76% (adjusted P = 0.009). Receiver operating characteristic curve analysis demonstrated that combining circFAM13B expression > 1.05 with clinical risk factors could effectively predict the risk of adverse ischemic events (AUC = 0.81, 95% CI: 0.69 to 0.92, P < 0.001). Kaplan-Meier survival analysis showed that patients with circFAM13B > 1.05 had a significantly higher risk of adverse ischemic events compared to those with circFAM13B ≤ 1.05 (P = 0.003). Multivariate logistic hazard analysis identified circFAM13B > 1.05 as an independent risk factor for adverse ischemic events in in ticagrelor-treated ACS patients (adjusted OR: 5.60, 95% CI: 1.69–18.50; P = 0.005). Conclusions: Platelet-derived circFAM13B could be utilized for predicting the antiplatelet responsiveness and efficacy of ticagrelor in patients with ACS.
- Open Access
- 1 June 2024
- Published by Taylor & Francis in Clinical Interventions in Aging
- Vol. ume 19, 1041-1050
Association of CHAT Gene Polymorphism rs3793790 and rs2177370 with Donepezil Response and the Risk of Alzheimer’s Disease Continuum
Background: Genetic variation plays an important role in drug response, there are few relevant studies on patients with Alzheimer’s disease continuum (ADC). Objective: This study focused on the associations between two single nucleotide polymorphisms (SNPs) (rs3793790 and rs2177370) located in the CHAT gene and donepezil response in ADC patients, and further evaluated the associations between the two SNPs and ADC. Material and Methods: According to 2018 National Institute on Aging and Alzheimer’s Association (NIA-AA) standard, amyloid β-protein positive (Aβ+) and negative (Aβ-) patients were recruited according to the Aβ-PET/CT standard. rs3793790 and rs2177370 were genotyped in buccal swab samples by using the MassARRAY system. We used the Mini Mental State Examination (MMSE) in Chinese version, caregiver evaluation, and prescribing behavior to assess therapeutic response during the 9-month period. Using logistic regression models, we analyzed the relationship between the two SNPs and donepezil response in 58 Aβ+ patients treated with donepezil alone at the initial diagnosis of ADC. We also explored a probable link between the two SNPs and ADC in 147 Aβ+ and 73 Aβ– patients using a logistic regression analysis. Results: The chance of donepezil response was higher in patients with the G allele of rs3793790 and/or the A allele of rs2177370 than in those without (odds ratio (OR) 6.83, 95% confidence interval (CI): 1.64– 28.49). Additionally, the rs3793790 variant was not associated with ADC, whereas the A allele in rs2177370 increased 1.51-fold the ADC risk (OR 2.51, 95% CI: 1.28– 4.95). Conclusion: The genetic variants of rs3793790 and rs2177370 were associated with the donepezil response, and rs2177370 may have a moderate relationship with the risk of ADC.
- 1 June 2024
- Published by Taylor & Francis in Clinical Interventions in Aging
- Vol. ume 19, 1041-1050
Open AccessAssociation of CHAT Gene Polymorphism rs3793790 and rs2177370 with Donepezil Response and the Risk of Alzheimer’s Disease Continuum
Background: Genetic variation plays an important role in drug response, there are few relevant studies on patients with Alzheimer’s disease continuum (ADC). Objective: This study focused on the associations between two single nucleotide polymorphisms (SNPs) (rs3793790 and rs2177370) located in the CHAT gene and donepezil response in ADC patients, and further evaluated the associations between the two SNPs and ADC. Material and Methods: According to 2018 National Institute on Aging and Alzheimer’s Association (NIA-AA) standard, amyloid β-protein positive (Aβ+) and negative (Aβ-) patients were recruited according to the Aβ-PET/CT standard. rs3793790 and rs2177370 were genotyped in buccal swab samples by using the MassARRAY system. We used the Mini Mental State Examination (MMSE) in Chinese version, caregiver evaluation, and prescribing behavior to assess therapeutic response during the 9-month period. Using logistic regression models, we analyzed the relationship between the two SNPs and donepezil response in 58 Aβ+ patients treated with donepezil alone at the initial diagnosis of ADC. We also explored a probable link between the two SNPs and ADC in 147 Aβ+ and 73 Aβ– patients using a logistic regression analysis. Results: The chance of donepezil response was higher in patients with the G allele of rs3793790 and/or the A allele of rs2177370 than in those without (odds ratio (OR) 6.83, 95% confidence interval (CI): 1.64– 28.49). Additionally, the rs3793790 variant was not associated with ADC, whereas the A allele in rs2177370 increased 1.51-fold the ADC risk (OR 2.51, 95% CI: 1.28– 4.95). Conclusion: The genetic variants of rs3793790 and rs2177370 were associated with the donepezil response, and rs2177370 may have a moderate relationship with the risk of ADC.